Understand the source comparison
Peptides Thyroid Medication Safety: Comparison of Interaction Risk
Growth Hormone Secretagogues (MK 677, GHRP-2) Elevates IGF-1, suppresses TSH via negative feedback Dose ≥4 hours after thyroid medication TSH suppression 20–35% in first 8 weeks High interaction risk. Monitor TSH monthly during initial 12 weeks GLP-1 Agonists
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Growth Hormone Secretagogues (MK 677, GHRP-2)
- Elevates IGF-1, suppresses TSH via negative feedback
- Dose ≥4 hours after thyroid medication
- TSH suppression 20–35% in first 8 weeks
- High interaction risk. Monitor TSH monthly during initial 12 weeks
- GLP-1 Agonists (semaglutide analogs)
- Delays gastric emptying, reduces levothyroxine absorption peak
- Reduces T4 bioavailability 15–25% if co-administered
- Moderate risk. Separation eliminates absorption interference
- Thymus Peptides (Thymalin)
- Modulates T-cell activity (relevant in autoimmune thyroid disease)
- No direct absorption interaction
- Unpredictable in Hashimoto's or Graves' patients
- Use only with thyroid antibody monitoring
- Nootropic Peptides (Cerebrolysin, Dihexa)
- No known thyroid receptor interaction
- Standard 60-minute post-thyroid-med wait sufficient
- No documented TSH or T4 impact
- Minimal interaction risk. Proceed with standard timing
- Collagen Peptides (oral)
- Competes for intestinal amino acid transporters
- Dose ≥2 hours after thyroid medication
- Reduces levothyroxine absorption 10–15% if co-administered
- Low risk with proper timing. Easily avoided